How should a senior executive evaluate CEO jobs in India?

Separate succession, professionalisation, growth reset, portfolio repair and promoter transition because each creates a different first-year contract. Ask which event triggered the search, which prior approach no longer works and which result would cause directors to call the appointment successful. Treat that distinction as the first gate. Keep contrary evidence with its source. Do not let interview momentum settle it.

Write a one-page mandate hypothesis linking the trigger, three non-delegable outcomes and the decisions required to reach them. Test that hypothesis independently with the chair, controlling shareholder and lead director before allowing chemistry to substitute for alignment. A broad ambition to accelerate growth is not an appointment thesis; absent a named enterprise problem and an accountable sponsor, scope remains unverified.

A CEO search can be presented as a growth appointment even when the actual trigger is succession risk, an exhausted promoter compact or a portfolio that the board has postponed confronting. Those explanations imply different authority, timing and first-year measures. Ask for the board-approved mandate, the event that opened the search and the operating result attached to the appointment. Then compare the chair's account with those of the controlling shareholder and lead independent director. If they agree only on the title, the candidate may inherit several unresolved jobs rather than one governable mandate. The consequence is not merely a difficult first hundred days. It is accountability for outcomes whose cause and sequence were never agreed. Treat a change in trigger during interviews as a material reset, not helpful colour. Stop if no authorised sponsor will state the enterprise problem, the decisions the CEO may take and the result directors will use to judge the appointment.

Map authority over capital allocation, executive appointments, business exits, pricing exceptions and promoter-linked relationships. A role can carry full P&L language while reserving the decisions that shape that P&L for a family office, global parent or informal operating committee. Turn the gap into an authority question. Ask for one contested decision. Record who resolved it and how.

Ask for recent examples of a comparable decision, who initiated it, who challenged it and who signed it. Convert each answer into a decision-rights map and distinguish consultation from consent, because the two are routinely blurred in executive conversations. Do not infer authority from reporting line, board seat or title; authority is established through repeatable decision mechanisms and evidence of how disagreement is resolved.

A chief executive can hold the highest operating title while the decisions that shape the P&L remain with a promoter, family office, global parent or informal investment committee. The contradiction appears when full accountability is promised alongside reserved capital, leadership and portfolio choices. Request the current reserved-matters schedule and replay two recent decisions: a senior appointment and a material investment or exit. Identify who proposed, challenged, approved and funded each action, including any route outside the formal board. The practical consequence is whether the incoming CEO can change the system or can only explain its results. A board seat does not cure a veto exercised elsewhere, and personal access does not create repeatable authority. Record every gap between the mandate and precedent as a condition requiring named resolution. Stop when the organisation will not disclose the governing forum, when examples contradict the proposed scope, or when authority is deferred until after performance has already become the CEO's responsibility.

A board may endorse transformation in principle while protecting legacy leaders, dividend expectations or businesses that the transformation must confront. Test whether directors share one diagnosis, what trade-offs they have already accepted and where support could fracture under quarterly pressure. Test the commitment under visible pressure. Record who accepts the cost. Name who can reverse the choice.

Present two realistic first-year choices that force a trade-off between near-term optics and mandate health. Listen for whether sponsors debate the choices with specificity or retreat to generic reassurance; the response reveals the practical sponsorship available after appointment. Warm personal access to a chair is not equivalent to institutional sponsorship when other directors or owners can reverse the operating compact.

Boards often endorse transformation until the programme threatens a legacy leader, dividend expectation, related-party relationship or protected business. That is the central sponsorship contradiction in a CEO mandate. Test it with a concrete first-year choice that trades near-term optics for the outcome directors say they want. Ask each material sponsor what they would defend, which cost they would accept and where disagreement would be resolved. Board minutes, prior transformation decisions and the treatment of an earlier executive provide stronger evidence than private reassurance. If sponsors offer incompatible protections, the CEO may become the mechanism through which owners postpone their own conflict. The executive consequence is a mandate that narrows precisely when change begins to matter. Write the sponsor compact before appointment and circulate it for correction. Stop if directors will not acknowledge the foreseeable trade-off, if no forum can bind the coalition, or if support depends on one relationship that other owners can reverse.

Examine leadership bench depth, monthly operating data, locked investments, unresolved compliance matters and the dependency on a few customer or supplier relationships. The purpose is not to audit the company from outside; it is to identify which assumptions the first hundred days would need to verify. Price the uncertainty before it compounds. Separate verified conditions from working assumptions. Give each gap an accountable source.

Create an inherited-system register with confidence labels: observed, sponsor-asserted, management-asserted and unknown. Link each unknown to a decision deadline so that diligence becomes a sequence, not an unlimited request for private information. Without authorised diligence, these factors remain hypotheses; they should shape questions and conditions, never be presented as facts about a particular employer.

A persuasive enterprise ambition can conceal an inherited system unable to produce the information, talent or capital discipline required to deliver it. For a CEO candidate, the contradiction is between promised strategic latitude and a first year consumed by basic operating repair. Request a sample board pack, the monthly performance cadence, a current organisation view, committed capital projects and a register of material compliance or customer dependencies that may be shared lawfully. These sources do not constitute an outside audit, but they reveal where management already distinguishes fact from estimate. Map each unknown to the decision it could delay and the executive who owns verification. The consequence may be a different sequencing contract, additional transition support or a revised performance baseline. It may also make the mandate unexecutable. Stop if sponsors insist on fixed outcomes while denying access to the information needed to set a credible base case, or if inherited constraints are repeatedly described as matters the incoming CEO can discover after joining.

Repeated changes in mandate wording, unexplained stakeholder additions, refusal to define reserved matters and pressure to accept before board alignment are structural signals. They indicate that the organisation may be purchasing optionality while transferring execution risk to the incoming leader. Write the threshold before final-stage momentum. Reopen only on authorised evidence. Keep reassurance outside the proof record.

Pre-commit three exit rules and share them with a trusted adviser before final-stage chemistry intensifies. A useful rule names the missing evidence, the date by which it must appear and the consequence if it does not. Stopping is a decision-quality outcome, not a prediction that the enterprise will fail or that another executive could not accept the same conditions.

The integrity of a CEO process is visible in what remains stable as access, compensation and stakeholder attention increase. A search that begins with clear authority can deteriorate through revised mandate language, new veto holders, unexplained urgency or reluctance to document reserved matters. Maintain a chronology of each material claim, its source and any later change. Ask the authorised search lead to reconcile differences before another stage begins. The executive consequence of accepting unresolved movement is an appointment contract that the organisation can reinterpret after arrival while the CEO remains publicly accountable. A late improvement in economics should be evaluated separately because it cannot repair governance. Set three written conditions covering mandate, sponsor alignment and access to operating evidence, each with a deadline. Stop when the process repeatedly changes who owns the decision, when requested proof is replaced by chemistry, or when the candidate is pressed to commit before the board has agreed what it is appointing the CEO to do.